KYNB Kyntra Bio, Inc.

NASDAQ
$7.05

Kyntra Bio, Inc. (KYNB) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $3.33 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on August 13, 2026.

Kyntra Bio Missed Consensus Estimates
Thursday, August 13, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($3.33)
Rev est $1.97M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kyntra Bio, Inc.

Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease.

Sector

Healthcare

Industry

Biotechnology